Sanofi, Principia agree to develop multiple sclerosis drug candidate
2017年11月9日 - 8:58PM
Sanofi, Principia
agree to develop
multiple sclerosis drug candidate
-
Clinical-stage oral drug candidate
(PRN2246)
with the potential to treat multiple sclerosis
-
Principia to receive $40 million upfront
payment,
future milestone payments could total $765 million
Paris, France and South San Francisco, Calif -
November 9, 2017 - Sanofi will develop Principia Biopharma
Inc.'s experimental oral treatment that shows promise in multiple
sclerosis (MS) and, potentially, other central nervous system (CNS)
diseases.
Under the license agreement signed this week, Sanofi will develop
Principia's Bruton's tyrosine kinase (BTK) inhibitor (PRN2246),
which was designed to access the brain and spinal cord by crossing
the blood-brain barrier and impact immune cell and brain cell
signalling. PRN2246 is currently in clinical development.
"Our agreement with Principia is an example of Sanofi's strategic
commitment to build our drug discovery and development pipeline in
MS and neurological diseases," says Rita Balice-Gordon, PhD, Global
Head of MS/Neuroscience Therapeutic Research Area at Sanofi.
"Complementing our own internal R&D expertise, external
relationships like this may accelerate delivery of new treatments
to patients living with these serious diseases."
"Sanofi is
an ideal partner for PRN2246. The agreement allows Principia to
maximize the BTK opportunity in neurology with a strong partner for
PRN2246 while focusing internal resources on our lead BTK inhibitor
in another therapeutic area," said Martin Babler, Chief Executive
Officer of Principia Biopharma. "PRN2246 is a blood brain barrier
crossing, highly potent BTK inhibitor, that we believe is
especially well suited for the treatment of MS and other
neurological disorders."
Sanofi to receive exclusive, worldwide license
Under the terms of the agreement, Principia will grant Sanofi an
exclusive, worldwide license to develop and commercialize PRN2246.
Sanofi will pay Principia a $40 million upfront payment, future
milestone payments that could total $765 million and royalties on
product sales. Principia has the option to co-fund Phase 3
development, in exchange for either increased royalties on
worldwide product sales or a profit and loss sharing arrangement in
the United States.
The transaction is expected to close in the fourth quarter of 2017,
subject to customary regulatory approvals.
Sanofi is a leader in MS
Sanofi Genzyme, the specialty care global business unit of Sanofi,
currently has two marketed MS medicines available around the world,
and programs in research and development to address MS, potentially
through neuroprotection and remyelination in addition to
anti-inflammatory mechanisms. Sanofi is committed to discovering
and developing new treatment options for people living with
MS.
About Principia Biopharma
Principia Biopharma Inc., a private, clinical-stage
biopharmaceutical company, has created a revolutionary new way to
design and develop oral small molecule therapies that are more
potent, selective, durable and safer than currently available
drugs. The Company has utilized its proprietary Tailored
Covalency(TM) technology to develop a portfolio of drug candidates
that exhibit antibody-like specificity to benefit patients with
autoimmune and inflammatory diseases and cancer. PRN1008, a
reversible covalent BTK inhibitor, is currently being evaluated in
a Phase 2 clinical trial in patients with pemphigus, an orphan
autoimmune disease. PRN1371, a covalent FGFR1-4 inhibitor, is
currently being evaluated in a Phase 1 clinical trial in cancer
patients with various solid tumors. PRN2246, a low dose
covalent BTK inhibitor which crosses the blood brain barrier,
recently has initiated a Phase 1 clinical trial in healthy
volunteers. For more information, please visit the Company's
website at www.principiabio.com.
|
|
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
|
|
Sanofi Media Relations Contact Jack
Cox
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com
|
Sanofi Investor Relations Contact George
Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
|
|
Principia Media Contact: Kelly Boothe
Pure Communications
Tel: +1 (415) 946-1076
kboothe@purecommunications.com
|
Principia Investor Contact: Christopher Chai, Principia
Tel: +1 (650) 416-7730
|
|
Sanofi Forward-Looking Statements
This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates regarding the clinical development of and potential
marketing approvals for the product. Forward-looking statements are
generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans", "would be" and similar
expressions. Although Sanofi's management believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development of
the product, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve the product or
biological application that may be filed for the product as well as
their decisions regarding labeling and other matters that could
affect the availability or commercial potential of the product, the
absence of guarantee that the product if approved will be
commercially successful, risks associated with intellectual
property, future litigation, the future approval and commercial
success of therapeutic alternatives, and volatile economic
conditions, as well as those risks discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2016. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
|
|
PDF Version
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Sanofi via Globenewswire
Sanofi (EU:SAN)
過去 株価チャート
から 3 2024 まで 4 2024
Sanofi (EU:SAN)
過去 株価チャート
から 4 2023 まで 4 2024